July 23, 2019 / 10:41 AM / a month ago

Biogen profit rises 72%

July 23 (Reuters) - Drugmaker Biogen Inc reported a 72.4% rise in second-quarter profit on Tuesday, boosted by higher sales of its multiple sclerosis treatment Tecfidera and lower research and development costs.

Net income attributable to the company rose to $1.49 billion, or $7.85 per share, in the quarter, from $866.6 million, or $4.18 per share, a year earlier. (bit.ly/2LDqLL6)

Total revenue rose to $3.62 billion from $3.36 billion. (Reporting by Saumya Sibi Joseph and Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below